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Abstract
ThetreatmentofhyponatraemiaduetoSIADHisnotalways
as straightforward as it seems. Although acute treatment
with hypertonic saline and chronic treatment with fluid re-
striction are well established, both approaches have severe
limitations. These limitations are not readily overcome by
addition of furosemide, demeclocycline, lithium or urea
to the therapy. In theory, vasopressin-receptor antagonists
would provide a more effective method to treat hypona-
traemia, by virtue of their ability to selectively increase
solute-free water excretion by the kidneys (aquaresis). In
this review we explore the limitations of the current treat-
ment of SIADH and describe emerging therapies for the
treatment of SIADH-induced hyponatraemia.
Keywords: hyponatraemia; SIADH; urea; vasopressin;
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Introduction
Hyponatraemia is associated with increased morbidity and
mortality, but it is frequently under-recognized and un-
dertreated [1]. In the absence of end-stage renal failure,
hyponatraemia usually represents a state of vasopressin-
induced water retention. The cause of the increased plasma
vasopressin concentration can be volume depletion, in
whichcasethewaterretentioncanbeviewedasappropriate
from a circulatory point of view. Another type of hypona-
traemia occurs in so-called hypervolaemic states (cardiac
failure, liver cirrhosis). However, in still other instances
vasopressin-induced water retention occurs as a result of
a hyper- or hypovolaemia-independent increase in vaso-
pressin secretion. There may also be an increase in the
renal actions of vasopressin on its receptor [2]. In patients
with the latter two entities, antidiuresis is deemed ‘inappro-
priate’, hence the name Syndrome of Inappropriate Anti
Diuretic Hormone secretion (SIADH). For instance, un-
controlled vasopressin secretion may occur in patients with
small-cell cancer of the lung. In these patients urine is not
maximally dilute, despite the reduction in serum osmolal-
ity. In some patients SIADH is episodic in occurrence, but
in others it is chronic, lasting for years. In such subjects,
long-term treatment may be necessary. Although there are
several approaches to the treatment of SIADH, none of the
present treatment options is without problems [3].
Before delving into specific forms of treatment, one
should consider the question: ‘Are all patients with SIADH
alike?’Althoughvasopressinlevelsappearlargelyindepen-
dentofserumosmolalityinroughlyonethirdofthepatients,
manypatientsexhibitsomeformofvasopressinresponsive-
ness albeit at a lower serum osmolality [2]. In such cases,
excessive fluid intake appears equally important to vaso-
pressin release in the initiation of hyponatraemia. This may
be due to regulation at a lower setpoint (i.e. a ‘reset os-
mostat’) [2]. Because serum osmolality is still regulated in
these patients, a correction of the hyponatraemia causes ex-
cessive thirst, which leads to persistent hyponatraemia that
canbeerroneouslyinterpretedas‘treatmentfailure’.Inrare
patients a renal form of inappropriate antidiuresis has been
described, due to an activating mutation in the vasopressin
receptor [4]. In these patients plasma vasopressin levels are
low or even undetectable at all levels of serum osmolality.
Notallpatientswithdrug-inducedSIADHhavemeasurable
plasma levels of vasopressin, suggesting that modulation
ofthevasopressin-receptor aquaporin-2 signallingpathway
may also occur [5]. Indeed, in SIADH the range of plasma
copeptinlevels(astable39-aminoacidpeptidederivedfrom
thesameprecursorproteinasvasopressin)wassignificantly
lower than in patients with hypovolaemic hyponatraemia
[6]. Plasma copeptin levels give an estimate of long-term
vasopressin secretion, much like HbA1C percentages in
diabetes; this implies that vasopressin-independent mecha-
nisms may be operative [7]. Moreover, it must be remem-
bered that thirst and drinking play an important role in the
pathogenesis of hyponatraemia. This was illustrated in rats
in which exogenous DDAVP was followed by suppression
of thirst and only the combination with forced water intake
led to hyponatraemia [8].
Current treatment options
Water restriction
As the hypo-osmolality in SIADH results from a relative
abundance of water in the intra- and extracellular volumes,
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maintained by a reduced ability to excrete water, restriction
of oral water intake is a logical option [9]. In general a fluid
restriction of 0.8 L/day is advised. This includes all fluids,
including water contained in food. As the obligatory diure-
sis due to osmole excretion, together with insensitive water
loss through the skin, gut and lungs, generally exceeds this
amount, a small amount of free water is lost in the urine.
This strategy leads to a slow correction rate. In these pa-
tients, the advised rate of correction should be viewed as
a maximum rather than a target [10]. At the present time,
water restriction is generally considered the treatment of
choice for hyponatraemia secondary to SIADH. However,
many patients have difficulties complying with prolonged
fluid restriction, possibly because they experience “inap-
propriate” thirst, and hyponatraemia may recur [11]. More-
over, in patients with SIADH part of the water overload
may be due to downward resetting of the osmotic threshold
for thirst [12]. As thirst is particularly difficult to suppress
[13], water restriction in SIADH frequently leads to non-
compliance in the long run. The use of water restriction is
insufficient to treat acute severe hyponatraemia and should
not be employed in severely symptomatic hyponatraemia,
in which a more rapid correction rate is necessary.
Isotonic saline
AsurineosmolalityinSIADHfrequentlyrangesfrom400–
600 mOsmol/kg, infusion with isotonic saline may lead to
a further decrease in serum osmolality. A frequent miscon-
ception is that isotonic saline (300 mOsmol/kg) is hyper-
tonic to the patient and should therefore lead to correction
ofhyponatraemia.However,whentheinfusate(Na)islower
thanthepatient’surinary(Na+K),theuseofisotonicsaline
represents a source of free water. This process is referred to
as desalination [14]. This is most likely to occur if urinary
osmolality is above 530 mOsm/kg, as some patients with
SIADH and lower urinary osmolalities have been success-
fully treated with isotonic saline [15].
Hypertonic saline
If a patient is symptomatic due to a rapid decrease in
serum sodium concentration, treatment with hypertonic
saline should be considered [16]. No randomized trials
have ever been performed comparing different approaches
to acute correction of hyponatraemia, but the use of hyper-
tonicsalineinthiscircumstanceiswidelyaccepted[11,17].
Hypertonic saline may or may not be combined with a loop
diuretic,dependingonthevolumestatusofthepatient[18].
Severalformulaehavebeendeveloped toestimatetheef-
fect of a given infusate on the serum sodium concentration.
Asimpleruleofthumbthatwasrecentlyproposed:Inorder
to induce a correction rate of 1 mmol/L per hour, using 3%
NaCl, one should infuse the body weight as millilitres per
hour (i.e. a man with a body weight of 70 kg will increase
by approximately 1 mmol/L per hour when infused with
3% NaCl at a rate of 70 mL/h) [19].
TheAdrogu´ e–Madiasformulahasbeenmostextensively
studied [11,20,21]. This formula was shown to predict cor-
rection rates using hypertonic saline with reasonable accu-
racy, and is listed below. The formula derives the change in
plasma sodium concentration ( [Na]) that is produced by
1 l of infusate with given sodium and potassium concen-
trations ([Na]infusate + [K]infusate) from the present serum
sodium concentration and the (new) volume of distribution
(total body water + 1).
 [Na] = ([Na]infusate + [K]infusate)
−serum [Na]/total body water + 1.
It should be noted that this formula does not consider on-
going urinary loss of sodium and potassium. In addition, it
sometimes underestimates the rate of correction of hypona-
traemia following hypertonic saline, leading to potential
over correction [21]. Therefore, irrespective of the way the
initial rate of infusion was derived, a close follow-up of the
patient and frequent determinations of the serum sodium
concentration and/or urine osmolality are essential.
Loop diuretics
In order to increase free water excretion rates, loop diuret-
ics have proven effective in the treatment of SIADH. This
may be related to an inhibition of the ability of the kidney
to maintain a medullary concentration gradient [22]. This
treatment, however, is not useful in long-term treatment of
SIADH, as a few results of long-term treatment have been
reported and this strategy is generally reserved to the acute
phase of correction [23]. In patients in which fear exists for
the development of pulmonary oedema during treatment
with hypertonic saline, treatment with loop diuretics can
help in avoiding vascular overfilling.
Demeclocycline
Nephrogenic diabetes insipidus (NDI) is a frequent renal
sideeffectofdemeclocyclinehydrochloride,agroupItetra-
cycline derivative. For this reason, it is occasionally used to
treat SIADH. Its use dates back to the 1970s [24] and the
drug has been employed chronically, most often in patients
with SIADH due to a malignancy [25]. However, the agent
has frequent side effects, such as nausea and skin photo-
sensitivity. Moreover, demeclocycline has also been shown
to cause nephrotoxicity [26], in some cases leading to irre-
versible renal failure [27]. At present, it is unknown where
it interferes with the vasopressin-aquaporin signalling cas-
cade [28]. It causes NDI in roughly 70% of cases and it
takes 2–3 days before it becomes effective.
Lithium
Like demeclocycline, lithium carbonate causes NDI in
some 65% of patients. Patients with bipolar disorder gener-
allyrespondwelltolithiumtreatment,butthesideeffectson
urinaryconcentrating abilityoftencausepolyuriaandpoly-
dipsia. Lithium appears to enter the principal cells of the
collectingductthroughtheepithelialsodiumchannelENaC
and reduces aquaporin-2 expression [29]. Long-term treat-
ment with lithium may induce tubulo-interstitial nephritis
that can lead to irreversible NDI and end-stage renal failure
[30]. The effect of lithium takes approximately 4 days to
set in. The serum lithium concentration must be followediii14 R. Zietse et al.
closely in order to prevent renal toxicity. For these reasons,
the use of lithium to treat SIADH has been mostly aban-
doned. In animal models, however, lithium has been shown
to augment the effects of aquaretic agents [31].
Urea
Urea is a major osmotic constituent of urine, accounting
for half of the daily osmolar load excreted. In classic ex-
periments, Brodsy and Rapoport demonstrated that as so-
lute excretion increases, the osmolality of urine decreases,
despite maximal doses of vasopressin [32]. This has led
investigators to pursue the effects of increasing free water
clearance by administering urea [33]. Urea can be given
by mouth, either as a powder or in capsules, and thus re-
sults in an osmotic diuresis. Due to its bitter taste, its use
has not met wide acceptance, but Decaux et al.h a v er e -
ported favourable results of long-term treatment [34]. In-
terestingly, in animal models the use of urea appears to
protect against brain damage and myelinolysis during rapid
correction of hyponatraemia [35,36]. Both a high-protein
diet and urea administration ameliorated hyponatraemia in
rodents and was associated with a decrease in natriuresis
[37]. Its use appears to be restricted to patients with mod-
erately elevated urinary osmolalities [38].
Extracorporeal treatments
Althoughrapidcorrectionofhyponatraemiamayoccurdur-
ing haemodialysis, in some instances leading to pontine
myelinolysis [39], more gradual forms of dialysis treat-
ment have been advocated. Veno-venous haemofiltration
has been shown to induce a more gradual correction of
hyponatraemia [40] and other forms of slow dialysis treat-
ment, such as slow low-efficiency daily dialysis (SLEDD),
may be equally effective [41]. However, as most forms of
continual renal replacement therapy are performed on in-
tensive care wards, this approach to treat SIADH would
lead to a steep increase in costs. In patients with established
renal failure, however, dialytic or convective therapies are
the treatment of choice.
Vaptans
As current forms of treatment of SIADH have serious limi-
tations, the development of the new class of orally available
aquaretic agents was received with great expectation [42].
In the absence of treatment directed at aquaporin-2 expres-
sion, the next most specific treatment of SIADH would be
to inhibit the effects of vasopressin, using a vasopressin-
receptor antagonist, also called ‘vaptans’ (Figure 1) [17].
Inthepast15years,severalstudieshaveexploredtheuseof
these aquaretic drugs in hyponatraemia (Table 1). In these
studies, an effort was made to distinguish between patients
with euvolaemic, hypervolaemic and hypovolaemic forms
of hyponatraemia, because giving a vaptan in the presence
of hypovolaemia would have detrimental effects. One of
the diseases that appeared to be a prime indication for the
newvaptan-classofdrugswasSIADH.Theeffectivenessof
tolvaptan,aselectivevasopressinV2-receptorantagonist,in
increasing serum sodium concentrations was demonstrated
in the SALT-1 and SALT-2 trials (Figure 2) [43]. Although
these 30-day trials of tolvaptan also included patients with
hyponatraemia due to heart failure and liver cirrhosis (‘hy-
pervolaemichyponatraemia’),some40%oftheparticipants
were diagnosed with SIADH. As euvolaemia is often dif-
ficult to assess in such patients [44], saline infusions were
used when there was doubt concerning the volume status.
Participating patients were no longer required to adhere to
a fluid restriction. In general, treatment appeared to be ef-
fective and to have an acceptable safety profile. The most
common side effects were increased thirst and a dry mouth.
The desirable rates of correction of serum sodium were
exceeded in only 4 out of 223 patients, and an overshoot
of the sodium concentration to levels above 146 mmol/L
was observed in no more than 4 patients [43]. However, the
protocol mandated strict monitoring of the serum sodium
concentration. It remains to be seen how safe the agent will
turn out to be in everyday clinical life.
As these studies included patients with varying underly-
ing disease, and no data were given for individual patient
groups, it remains difficult to use the outcome of this study
as guidance for therapeutic intervention in SIADH. Al-
though scores on the Physical Component Summary of the
SF-12 health survey did not differ significantly between
treated and untreated subjects, patients included in SALT-1
reported a significant increase in the Mental Component
Summary [43].
A study on the effects of conivaptan, a vasopressin
V1a/V2-receptor antagonist, in hyponatraemia demon-
strateditsefficacyinincreasingserumsodium,butincluded
predominantly heart failure patients [45]. Although coni-
vaptan may have effects similar to tolvaptan, conivaptan is
only available as a parenteral preparation.
Following these efficacy trials, a major study was under-
taken attempting to demonstrate differences in outcome of
heart failure patients treated with tolvaptan, the EVEREST
trial [46]. This trial failed to show significant differences in
mortality compared with placebo.
A few studies have been performed to study the efficacy
of vaptans specifically in SIADH patients. Several studies
of short duration reported that vaptans were efficacious in
increasing serum sodium concentrations [47,48]. There is,
however, a paucity of long-term observations in SIADH.
In one open-label extension of a satavaptan trial, SIADH-
patientsremainednormonatraemicupto12monthsoftreat-
ment[49].Inthisstudy,treatmentwaswelltoleratedandno
patients were excluded due to side effects, although an in-
crease in thirst was reported. Recently, two controlled trials
of conivaptan were reported, both performed in a limited
number of patients with euvolaemic or hypervolaemic hy-
ponatraemia, mostly due to SIADH [50,51]. Both studies
demonstrated efficacy of conivaptan to increase free water
clearance and to correct hyponatraemia. In a subsequent
report on a subgroup of patients that were considered eu-
volaemic (including a higher percentage of patients with
SIADH), similar results were obtained [52].
Although long-term studies performed specifically in
SIADH patients are awaited, there is little doubt that these
agents will be effective in the treatment of chronic hypona-
traemia [53,54]. However, at present, all treatment-related
recommendations are based on expert opinion and thereTreatment of SIADH iii15
Fig. 1. The vasopressin V2-receptor, vasopressin, and a non-peptide vasopressin receptor inhibitor (OPC-21268). (A) Vasopressin-2 receptor with
its seven transmembrane helices. Red dots indicate the loss-of function mutations in patients with nephrogenic diabetes insipidus, while the two
green squares indicate to gain-of-function mutations in patients with nephrogenic syndrome of inappropriate antidiuresis. (B) Molecular modelling
of antagonist activity of vaptans. The proposed mechanism is that the vaptans penetrate deeper and more selectively into the binding pocket of the
vasopressin-receptor type 2 than native vasopressin without activating it, thereby exerting an antagonistic effect. Reprinted from The Lancet, 371,
Decaux, G., A. Soupart, and G. Vassart, Non-peptide arginine-vasopressin antagonists: the vaptans. 1624–1632. Copyright 2008, with permission from
Elsevier.
are several issues that need to be addressed before final
recommendations can be made.
In which patients could vaptans be used? In treating
patients with moderate to severe symptomatic hypona-
traemia, the treating physician faces a classic dilemma.
The physician needs to avoid treating acute hyponatraemia
too slowly (in order to prevent damage from cerebral
oedema)buthealsoneedstoavoidtreatingchronichypona-
traemia too quickly (in order to reduce the risk of osmoticiii16 R. Zietse et al.
Fig. 2. Effect of Tolvaptan on serum sodium concentration in SALT-1 and SALT-2 trials. Comparison of mean serum sodium concentrations according
to the day of patient visit in patients with hyponatraemia (HN) due to SIADH, liver cirrhosis or congestive heart failure receiving either tolvaptan
(circles) or placebo (squares). Asterisks (P < 0.001) and daggers (P < 0.01) indicate significant differences. SALT-1 and SALT-2 refer to Study of
Ascending Levels of Tolvaptan in hyponatraemia 1 and 2, two identical phase 3 randomized controlled trials in the United States of America (SALT-1)
and Europe (SALT-2). Panel A shows the results of all patients, panel B of those with marked hyponatraemia (baseline serum sodium between 125
and 127 mmol/L) and Panel C of those with mild hyponatraemia (baseline serum sodium approximately 132 mmol/L). Tolvaptan was given orally for
30 days followed by a 7-day observation period. Reprinted with permission from Massachusetts Medical Society (Schrier, R.W. et al., Tolvaptan, a
selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med, 355(20), 2099–2112) C   2006 Massachusetts Medical Society. All
rights reserved.Treatment of SIADH iii17
Table 1. Vasopressin-receptor antagonists: characteristics and results from studies
Vasopressin Route of Urine Urine
Agent receptor administration volume osmolality Disorders studied References
Conivaptan V1a and V2 Intravenous or oral ↑↓ SIADH, CHF [45,50,52,61–63]
Lixivaptan V2 Oral ↑↓ SIADH, CHF, cirrhosis [64–66]
Mozavaptan V2 Oral ↑↓ SIADH, cirrhosis [67,68]
Satavaptan V2 Oral ↑↓ SIADH, cirrhosis [49,69]
Tolvaptan V2 Oral ↑↓ SIADH, CHF, cirrhosis [43,46,70–72]
demyelination). The problem is that distinguishing acute
fromchronicandsymptomaticfromasymptomatichypona-
traemia is not always as simple as it sounds. Moreover,
the evidence upon which correction rates are based is rel-
atively small. In correction of severely symptomatic hy-
ponatraemia, a rapid increase of serum sodium is desirable.
An increase by as little as 2–4 mmol/L may relieve symp-
toms, and treatment should be interrupted once symptoms
abate, a safe serum sodium concentration is reached (gen-
erally ≥120 mmol/L), or a total magnitude of correction of
18 mmol/L is achieved [19]. When treating patients with
chronic hyponatraemia, adhering to correction rates less
than 10–12 mmol/L in the first 24 h (and < 18 mmol/L
in 48 h) will generally avoid osmotic demyelination [55],
although in patients with anorexia or hypokalaemia even
slower correction rates are advisable [56].
Present treatment options do not always lead to a pre-
dictable and well-controlled increase in serum sodium con-
centrations and calculations may lead to underestimating
rates of correction [21]. However, at present, the relative
efficacy of vaptans compared to hypertonic saline, is not
knowneither.Inpatientswithseveresymptoms(seizuresor
coma) possibly related to acute hyponatraemia, a rapid cor-
rectionrateisinitiallydesirableandthecurrenttreatmentof
choice is to give hypertonic saline. There is no documented
experience using vaptans in patients with serum sodium
concentrations below 120 mmol/L.
If vaptans were to be proven to lead to a more predictable
rise in serum sodium concentrations, either as initial treat-
mentorassequentialtreatmentfollowinghypertonicsaline,
withgreatereffectivenesscomparedtofluidrestriction,this
could potentially reduce the length of hospitalization and
thereby cost. Presently, no studies have been reported di-
rectly comparing the efficacy of hypertonic saline infusion
to that of treatment with vaptans.
Patients with chronic SIADH and persistently elevated
levels of vasopressin will also be obvious candidates for
oral vaptans. However, in patients with chronic, mild to
moderate, hyponatraemia (120–133 mmol/L) water restric-
tion has generally been the initial therapy [19]. However,
fluidrestrictionisusuallyaburdentothepatient,unreliable,
impractical and slow to work. It would seem that vaptans
would be especially suited for treatment of these patients.
As increased thirst is a frequent feature of hyponatraemia
in SIADH, in such patients vaptans may prove to be more
effective than fluid restriction. Indeed, in most studies re-
portedtodate,serumsodiumconcentrationswerecorrected
by vaptans, despite lifting of the fluid restriction [43,50].
Hence, vaptans may substantially improve the quality of
life in these patients.
In which patients should vaptans not be used? As previ-
ously mentioned, no data are available on the use of vap-
tans in the treatment of severe symptomatic hyponatraemia
(serum sodium <120 mmol/L), and it would seem pru-
dent not to treat these patients with a vaptan at the present
time. Until further data become available, hypertonic saline
should be given in these patients.
Oral vasopressin-receptor antagonists are contraindi-
cated in patients with hypovolaemic forms of hypona-
traemia, because the subsequent decrease in extracellular
fluid volume would be deleterious. In theory, when us-
ing selective V2-receptor antagonists, the subsequent water
diuresis in these patients would be restricted by a low distal
delivery [10]. As conivaptan also possesses V1a-receptor
inhibitory properties, that may cause hypotension in the
presence of hypovolaemic hyponatraemia, it may be even
more important to avoid treating hypovolaemic patients
with this specific drug. Obviously, volume replacement
with 0.9% saline (with frequent determinations of urine
output and serum sodium) would be the appropriate treat-
ment here.
The problem is that volume status is not always easy to
estimate clinically [57]. In general, if the sodium concen-
tration in the urine is above 40 mmol/L, in a patient with
preserved renal function, normal dietary salt intake and not
ondiuretics,onecanassumewithreasonable safetythatthe
patient is not volume depleted.
Althoughprobablyrare,insomepatientsfollowingasub-
arachnoidal haemorrhage renal salt wasting with cerebral
disease may occur. This problem was previously referred
to as cerebral salt wasting and is characterized by natri-
uresis despite volume depletion [58]. As volume status is
difficult to assess, these patients are difficult to distinguish
from SIADH patients, but should be treated with copious
infusions of 0.9% NaCl and not with a vaptan.
SIADHisadiagnosisperexclusionem,whichmeansthat
diuretic use and adrenal insufficiency should be excluded
beforeinitiatingaquaretictreatment.Interestingly,although
thiazide-induced hyponatraemia is typically classified as
‘hypovolaemic’, these patients rarely exhibit true volume
depletion [59] and hyponatraemia seems largely related to
vasopressin secretion and excess water intake [60]. In most
ofthesepatientsdiscontinuationofthediureticwillsuffice.
Finally, oral vasopressin-receptor antagonists are also
contraindicated in patients with anuria, volume depletion,
hypernatraemia or in those who cannot perceive thirst, and,
in addition, during pregnancy or breastfeeding.
How should treatment be monitored? Most studies on
vaptans that have been performed lasted for days to weeks.iii18 R. Zietse et al.
Althoughthecauseofhyponatraemiaisfrequentlyofatem-
porary nature (pulmonary disease, drug treatment), some
patients require chronic treatment (chronic SIADH). This
mayresultintheproblemofnotknowingwhentostoptreat-
mentwithavaptan.Ithasbeenassumedthattheoccurrence
of hypernatraemia would indicate the end of an indication.
However, there is a distinct possibility that thirst caused by
a rise in serum osmolality, could lead to increased water
intake that would prevent hypernatraemia. Therefore, one
may have to consider discontinuation of a vaptan every 6–8
weeks, in order to observe whether hyponatraemia recurs,
before treatment is continued.
Are all vaptans created equal? At present the aquaretic
agents can be divided into those that selectively inhibit the
V2-receptor and those that have a combined antagonistic
effect on V1a- and V2-receptors (Table 1). At present no
studies have directly compared the effectiveness of selec-
tive V2- and combined V1a/V2-receptor inhibition in hy-
ponatraemia,andthepracticalimportanceofthesefindings
remains to be determined.
Conclusion
Many more questions need to be answered before one can
make well-founded recommendations for the use of vap-
tans in treating patients with hyponatraemia due to SIADH.
Future trials should address the possible superiority of vap-
tans to hypertonic saline in treating acute hyponatraemia.
In chronic treatment, the advantages in terms of effective-
ness and quality of life, as compared to water restriction,
certainly require further study. However, as some of these
agents are now registered for the treatment of euvolaemic
hyponatraemia, one can only hope treating physicians will
applythesedrugswiththesameamountofcareasexhibited
in patients that were included in the recent trials.
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